CTOs on the Move

Guardian Pharmacy

www.guardianpharmacy.net

 
Guardian Pharmacy Services, headquartered in Atlanta, Georgia, is the nation’s third largest institutional pharmacy company and one of the fastest growing privately held companies in the state of Georgia. Founded in 2004, Guardian and its partner pharmacies focus on providing exceptional client service and patient care to long-term care customers in assisted living communities, skilled nursing facilities, hospice and behavioral health group homes. Guardian Pharmacy Services` business model allows partner pharmacies to operate as independent local businesses tailoring their services to the needs of customers in their respective markets. We take our responsibility to our customers and their residents very ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Funding

Guardian Pharmacy raised $60M on 07/16/2018

Similar Companies

Brighton Pharmaceuticals

Brighton Pharmaceuticals is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OmegaChem

OmegaChem is a Levis, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Taisho Pharmaceutical California

Taisho Pharmaceutical California is a Torrance, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Banner Pharmacaps Inc

Banner is a global gelatin-based drug delivery and specialty pharmaceutical company. We are committed to researching, developing and producing unique oral dosage forms for the Pharmaceutical Health Care Industry. Through our innovative technologies and

Oncternal

Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase 1 development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers. Based in San Diego, Oncternal is committed to advancing its pipeline rapidly and efficiently to bring patients a new wave of first-in-class cancer treatments.